Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Overview of Key Overnight Developments on August 13

Overview of Key Overnight Developments on August 13

金色财经金色财经2025/08/12 23:36
Show original

21:00 (UTC+8) - 7:00 Keywords: BitMine, Perplexity, Transak, Fonte Capital 1. Grayscale launches DeepBook and Walrus Trusts; 2. BitMine discloses plans to issue up to $20 billion in common stock; 3. Perplexity proposes $34.5 billion acquisition of Chrome browser; 4. Remittance giant Western Union is considering launching a US dollar stablecoin; 5. Fed mouthpiece: July CPI may not be enough to prevent a rate cut in September; 6. Kazakhstan's Fonte Capital launches Central Asia's first spot Bitcoin ETF; 7. Web3 payment infrastructure company Transak completes $16 million funding round; 8. Politico: Trump officials consider Fed Vice Chair Jefferson for Fed Chair position.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11